Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study
- PMID: 38101916
- PMCID: PMC11065621
- DOI: 10.3899/jrheum.2023-0721
Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study
Abstract
Objective: Systemic lupus erythematosus (SLE) flares are associated with increased damage and decreased health-related quality of life. We hypothesized that there is discordance between physicians' and patients' views of SLE flare. In this study, we aimed to explore patient and physician descriptions of SLE flares.
Methods: We conducted a qualitative descriptive study using in-depth interviews with a purposeful sample of patients with SLE (who met 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria) and practicing rheumatologists. Interviews were audio-recorded, transcribed, and analyzed using applied thematic analysis.
Results: Forty-two patient participants with SLE, representing a range of SLE activity, completed interviews. The majority described flare symptoms as joint pain, fatigue, and skin issues lasting several days. Few included objective signs or laboratory measures, when available, as features of flare. We interviewed 13 rheumatologists from 10 academic and 3 community settings. The majority defined flare as increased or worsening SLE disease activity, with slightly more than half requiring objective findings. Around half of the rheumatologists included fatigue, pain, or other patient-reported symptoms.
Conclusion: Patients and physicians described flare differently. Participants with SLE perceived flares as several days of fatigue, pain, and skin issues. Providers defined flares as periods of increased clinical SLE activity. Our findings suggest the current definition of flare may be insufficient to integrate both perceptions. Further study is needed to understand the pathophysiology of patient flares and the best way to incorporate patients' perspectives into clinical assessments.
Keywords: disease activity; fatigue; fibromyalgia; lupus nephritis; self-assessment; systemic lupus erythematosus.
Copyright © 2024 by the Journal of Rheumatology.
Conflict of interest statement
MEBC has received grant support from Pfizer, Exagen, Astra-Zeneca, GlaxoSmithKline, and Immunovant and consulting fees from GlaxoSmithKline, UCB, and Amgen. JLR has received grant support from Pfizer, Exagen, Astra-Zeneca and Immunovant and consulting fees from Eli Lilly, Immunovant, Amgen, GlaxoSmithKline, Aurinia, Janssen, and Ampel Biosolutions. DSP has received consulting fees from Immunovant and GlaxoSmithKline. AME has received grant support from Pfizer, Exagen, GlaxoSmithKline, and Immunovant and consulting fees from Amgen. All other authors have no conflicts of interest to disclose.
Similar articles
-
The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus.Lupus. 2024 Mar;33(3):266-272. doi: 10.1177/09612033241228343. Epub 2024 Jan 18. Lupus. 2024. PMID: 38238905 Free PMC article.
-
Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus.Qual Life Res. 2020 Dec;29(12):3251-3261. doi: 10.1007/s11136-020-02572-9. Epub 2020 Jul 18. Qual Life Res. 2020. PMID: 32683643
-
Using Clinical Characteristics and Patient-Reported Outcome Measures to Categorize Systemic Lupus Erythematosus Subtypes.Arthritis Care Res (Hoboken). 2021 Mar;73(3):386-393. doi: 10.1002/acr.24135. Arthritis Care Res (Hoboken). 2021. PMID: 31909888
-
Interventions for cutaneous disease in systemic lupus erythematosus.Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. Cochrane Database Syst Rev. 2021. PMID: 33687069 Free PMC article.
-
Predicting lupus flares: epidemiological and disease related risk factors.Expert Rev Clin Immunol. 2021 Feb;17(2):143-153. doi: 10.1080/1744666X.2020.1865156. Epub 2021 Jan 22. Expert Rev Clin Immunol. 2021. PMID: 33393397 Review.
Cited by
-
Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model.ACR Open Rheumatol. 2024 Dec;6(12):865-870. doi: 10.1002/acr2.11748. Epub 2024 Sep 29. ACR Open Rheumatol. 2024. PMID: 39344059 Free PMC article.
-
Pain in systemic lupus erythematosus: emerging insights and paradigms.Nat Rev Rheumatol. 2025 Aug 26. doi: 10.1038/s41584-025-01290-1. Online ahead of print. Nat Rev Rheumatol. 2025. PMID: 40858989 Review.
-
The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus.Lupus. 2024 Mar;33(3):266-272. doi: 10.1177/09612033241228343. Epub 2024 Jan 18. Lupus. 2024. PMID: 38238905 Free PMC article.
References
-
- Bandeira M, Buratti S, Bartoli M, et al. Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus. 2006;15:515–20. - PubMed
-
- Zhu TY, , Tam L-s, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum; 2009:1159–67. - PubMed
-
- Ugarte-Gil MF, , Acevedo-Vásquez E, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis; 2015:1019–23. - PubMed
-
- Corneloup M, , Maurier F, et al. Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. Rheumatology (Oxford); 2020:1398–406. - PubMed
-
- Stoll T, . Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford); 2004:1039–44. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous